Cite Filings / CATX / 0000093751-26-000703
Feed Companies Filings Check
Sign in
SCHEDULE 13G

Statement of Beneficial Ownership

Perspective Therapeutics, Inc. · Filed 2026-11-10 · Acc 0000093751-26-000703

Documents 1

  • SCHEDULE 13G Statement of Beneficial Ownership , xslSCHEDULE_13G_X02/primary_doc.xml

Around this filing

  • 2026-11-13 4 Chief Medical Officer bought 41,000 shares at an average $0.84 ($34,545)
  • 2026-11-12 SCHEDULE 13D/A Beneficial Ownership Report
  • 2026-11-12 4 Chief Executive Officer bought 47,000 shares at $0.81 ($37,943)
  • 2026-11-10 SCHEDULE 13G Statement of Beneficial Ownership
  • 2026-11-09 10-Q Quarterly Report
  • 2026-11-09 8-K Results of operations · Other events
  • 2026-08-07 SCHEDULE 13G Statement of Beneficial Ownership

Link to a passage

At least 12 characters, not counting spaces, so the link points to one passage.

External

  • SEC EDGAR (opens in new tab)

Stakes reported in this filing

Stake history · largest stake in each 13D and 13G

  1. 2026-11-12 SCHEDULE 13D/A · Lantheus Holdings, Inc. 3.9%
  2. 2026-09-23 SCHEDULE 13D/A · Lantheus Holdings, Inc. 7.7%
  3. 2026-09-04 SCHEDULE 13D/A · Lantheus Holdings, Inc. 10.0%
  4. 2026-08-07 SCHEDULE 13G · STATE STREET CORPORATION 5.3%
  5. 2026-07-29 SCHEDULE 13G · BlackRock, Inc. 6.8%
  6. 2026-07-20 SCHEDULE 13G · Millennium Management LLC 5.3%
  7. 2026-04-27 SCHEDULE 13G/A · BlackRock, Inc. 4.6%
Loading xslSCHEDULE_13G_X02/primary_doc.xml…

Connection lost

Reconnecting…

Cite Filings isn't responding

Reconnecting…